Viking Therapeutics Reports Q4/FY25 Results, Advances Oral VK2735 to Phase 3, and Expands Obesity Pipeline

summarizeSummary

Viking Therapeutics announced its Q4 and full-year 2025 financial results, reporting increased R&D expenses and net losses, while providing a positive corporate update on its obesity pipeline, including advancing oral VK2735 to Phase 3 and maintaining a strong cash position.

check_boxKey Events

• Oral VK2735 Advances to Phase 3

  Following positive Phase 2 results and FDA feedback, the oral formulation of VK2735 for obesity is planned to enter Phase 3 development in Q3 2026, expanding the drug's potential market.

• Subcutaneous VK2735 Phase 3 Trials Progress Rapidly

  Enrollment for the VANQUISH-1 Phase 3 trial for subcutaneous VK2735 in obesity is complete, exceeding its target, and VANQUISH-2 is nearing full enrollment, demonstrating strong clinical execution.

• Maintenance Dosing Study Fully Enrolled

  The Phase 1 maintenance dosing study for VK2735, evaluating various long-term regimens (including monthly subcutaneous and daily/weekly oral), is fully enrolled with data expected in Q3 2026.

• New Amylin Agonist IND Filing Planned

  Viking plans to file an Investigational New Drug (IND) application for its novel dual amylin and calcitonin receptor agonist (DACRA) in Q1 2026, further expanding its obesity franchise.

auto_awesomeAnalysis

Viking Therapeutics' latest 8-K filing, which includes its Q4 and full-year 2025 financial results and a comprehensive corporate update, signals significant progress in its obesity pipeline. While the company reported increased net losses and R&D expenses, these are directly attributable to the accelerated advancement of its lead drug candidate, VK2735, into late-stage clinical trials. The decision to move the oral formulation of VK2735 into Phase 3 development, alongside the ongoing Phase 3 VANQUISH trials for the subcutaneous formulation, significantly broadens the drug's market potential and competitive differentiation. The strong cash position of $706 million provides a substantial runway to fund these critical development milestones. Investors should view the increased R&D spend as an investment in future growth, validated by the rapid progression of multiple key programs and the expansion into a novel amylin agonist.